Population pharmacokinetics, enzyme occupancy, and 24S‐hydroxycholesterol modeling of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, in healthy adults

Soticlestat is a first‐in‐class, selective inhibitor of cholesterol 24‐hydroxylase (CH24H), which catabolizes cholesterol to 24S‐hydroxycholesterol (24HC) in the brain, in phase III development for Dravet syndrome and Lennox–Gastaut syndrome treatment. This study aimed to develop a model of soticles...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Wei, Facius, Axel, Wagner, Thomas, Tsai, Max, Asgharnejad, Mahnaz, Lahu, Gëzim, Vakilynejad, Majid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339692/
https://www.ncbi.nlm.nih.gov/pubmed/37212649
http://dx.doi.org/10.1111/cts.13517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339692/
https://www.ncbi.nlm.nih.gov/pubmed/37212649
http://dx.doi.org/10.1111/cts.13517

Ejemplares similares